The Food and Drug Administration has extended the review period for sparsentan in focal segmental glomerulosclerosis (FSGS).

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Nvidia and Eli Lilly unveiled a co-innovation AI Lab for drug discovery efforts. Nvidia announced a strategic collaboration ...

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX).

The overall tally of drug approvals is down from 114 in 2024, with the EMA ascribing that record number to post-pandemic pent-up demand. However, the agency is expecting momentum to be maintained in ...

Travere Therapeutics FY25 sales surged on Filspari, but the FDA FSGS label decision was delayed to April. Click here to read ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics recently reported that the FDA has extended its review of the supplemental New Drug Application for ...

The latest health news highlights Vietnam's cigarette tax initiative, the FDA's review extension for Travere's kidney drug, ...

Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

A fresh setback on the regulatory front was the development that put a damper on Travere Therapeutics ( TVTX 14.63%) stock on ...